TY - JOUR
T1 - Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist
AU - Neale, Robert F.
AU - Fallon, Scott L.
AU - Boyar, William C.
AU - Wasley, Jan W F
AU - Martin, Louis L.
AU - Stone, George A.
AU - Glaeser, Bruce S.
AU - Sinton, Christopher M.
AU - Williams, Michael
PY - 1987/4/7
Y1 - 1987/4/7
N2 - CGS 12066B is a novel pyrroloquinoxaline with selectivity for the serotonin-1B (5HT1B) recognition site as assessed by binding, biochemical and electrophysiological studies. The compound had an IC50 value of 51 nM at the 5HT1B recognition site as determined using the binding of [3H]5HT in the presence of 1 μM spiperone. At the 5HT1A receptor the compound had an IC50 value of 876 nM, providing a 5HT1A/5HT1B ratio of 17 in contrast to the putative 5HT1B selective agent trifluoromethylphenylpiperazine (TFMPP) which had a corresponding ratio of 3.6. The compound had minimal affinity for α1-, α2- and β-adrenoceptors and for dopamine D-1 and D-2 receptors. CGS 12066B, in contrast to TFMPP, which was inactive, was found to inhibit dorsal raphe cell firing with an ED50 value of 358 nmol/kg i.v. The corresponding values for the 5HT1A selective agonists 8-OH-DPAT and ipsapirone were 1.3 and 33 nmol/kg. CGS 12066B was also effective in decreasing rat brain 5-HTP concentrations and inhibiting in vitro 5HT release. The data obtained indicate that CGS 12066B is a reasonably active 5HT1B site agonist, which due to its selectivity as compared to compounds such as TFMPP, will be a useful tool for evaluating the physiological role of such receptors in the mammalian CNS.
AB - CGS 12066B is a novel pyrroloquinoxaline with selectivity for the serotonin-1B (5HT1B) recognition site as assessed by binding, biochemical and electrophysiological studies. The compound had an IC50 value of 51 nM at the 5HT1B recognition site as determined using the binding of [3H]5HT in the presence of 1 μM spiperone. At the 5HT1A receptor the compound had an IC50 value of 876 nM, providing a 5HT1A/5HT1B ratio of 17 in contrast to the putative 5HT1B selective agent trifluoromethylphenylpiperazine (TFMPP) which had a corresponding ratio of 3.6. The compound had minimal affinity for α1-, α2- and β-adrenoceptors and for dopamine D-1 and D-2 receptors. CGS 12066B, in contrast to TFMPP, which was inactive, was found to inhibit dorsal raphe cell firing with an ED50 value of 358 nmol/kg i.v. The corresponding values for the 5HT1A selective agonists 8-OH-DPAT and ipsapirone were 1.3 and 33 nmol/kg. CGS 12066B was also effective in decreasing rat brain 5-HTP concentrations and inhibiting in vitro 5HT release. The data obtained indicate that CGS 12066B is a reasonably active 5HT1B site agonist, which due to its selectivity as compared to compounds such as TFMPP, will be a useful tool for evaluating the physiological role of such receptors in the mammalian CNS.
KW - (Binding)
KW - 5HT recognition sites
KW - Dorsal raphe cell firing
UR - http://www.scopus.com/inward/record.url?scp=0023233787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023233787&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(87)90772-2
DO - 10.1016/0014-2999(87)90772-2
M3 - Article
C2 - 3496228
AN - SCOPUS:0023233787
SN - 0014-2999
VL - 136
SP - 1
EP - 9
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -